Compare Danaher Corporation (DHR) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs HCA Health Inc — how do they compare? Danaher Corporation trades at $219.23 (market cap $152.87B), while HCA Health Inc trades at $448.62 (market cap $96.35B). The key difference: Danaher Corporation is the larger of the two by market cap, and Danaher Corporation pays the higher dividend (0.74%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and HCA Health Inc for 76 Days on average.
| DHR | HCA | |
|---|---|---|
Market Cap | $152.87B | $96.35B |
Volume | 5,228,698 | 1,079,453 |
Sector | Health | Health |
52-Week High | $242.05 | $545.13 |
52-Week Low | $161.91 | $361.32 |
Typical Hold Time | 69 Days | 76 Days |
Enterprise Value | $175.08B | $146.88B |
Dividend Yield | 0.74% | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
HCA Healthcare (HCA) trades at $439.17, up 1.61% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $75.6 billion in 2025, with net income reaching $6.78 billion, and the company has beaten EPS estimates for three consecutive quarters. Recent news includes an upcoming Q3 2026 earnings call and the completion of the College of Health Care Professions acquisition, highlighting operational expansion.
The outlook remains positive with a consensus price target of $461.12, though risks include ongoing legal investigations and high debt levels. Earnings growth and cost controls support upside potential, but investors should monitor regulatory developments and payer-mix pressures that could impact margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
